Skip to content
lifestyle.timesla.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
June 2, 2026
Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026
May 28, 2026
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
May 25, 2026
Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus
May 24, 2026
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies
May 24, 2026
Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts
May 23, 2026
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation
May 22, 2026
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution
May 21, 2026
Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease
May 16, 2026
Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform
April 28, 2026
1
2
Next Page
→